Fig. 3
PARP inhibitors induce cellular senescence in HRP cancer cells. (A) Phase-contrast images of HRP cancer cells in treatment with olaparib. The indicated HRP cancer cell lines were treated with olaparib at 10 μM for 72 h treatment. Scale bars indicate 50 μm. (B) Representative images of SA-β-GAL staining in olaparib-treated HRP cancer cells. The indicated HRP cancer cell lines were treated with olaparib at 10 μM for 72 h treatment, followed by SA-β-GAL staining. Scale bars indicate 50 μm. (C) Phase-contrast images of HRP cancer cells in treatment with niraparib. The indicated HRP cancer cell lines were treated with olaparib at 10 μM for 72 h treatment. Scale bars indicate 50 μm. (D) Representative images of SA-β-GAL staining in niraparib-treated HRP cancer cells. The indicated HRP cancer cell lines were treated with olaparib at 10 μM for 72 h treatment, followed by SA-β-GAL staining. Scale bars indicate 50 μm. (E) Flow cytometry in Hela cells treated with olaparib. Forward-scatter (FSC) and side-scatter (SSC) histograms are shown. Black and red indicate cell treated with DMSO and olaparib at 10 μM for 72 h, respectively. (F) Flow cytometry in Hela cells treated with niraparib. FSC and SSC histograms are shown. Black and red indicate cell treated with DMSO and niraparib at 10 μM for 72 h, respectively. (G) SSC histograms in A549, A549-reporter, and MCAS cells in treatment with olaparib at 10 μM for 72 h. (H) SSC histograms in SKOV3 cells in treatment with niraparib at 10 μM for 72 h.
